RxDoctor Payments Data

Michael Green, MD

Radiation Oncology · Ann Arbor, MINPI 1053722918

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,156 of the $1,563 with a category attached, or 74.0%. Merck accounts for 83.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $1,306 and has fallen 90.4% since, to $126 in 2025.

$1,563in general payments, 2019–2025

Across 10 payments — averaging $156.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Elekta, Inc.$126
  • AstraZeneca$114
  • Boston Scientific$17
$236,320in research payments, 2019–2025

Across 4 payments — averaging $59,080 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$159K
  • Janssen Research & Development, LLC$75K
  • Pfizer$2K

What the payments were for

  • Travel & lodging$1,15674%
  • Food & beverage$40726%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck7$1,306
Elekta, Inc.1$126
AstraZeneca1$114
Boston Scientific1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,563 in reported general payments places this provider in the 75th percentile of 198 radiation oncology providers in Michigan.

See all radiation oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$52,520
Medicare patients
41
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →